Neurol. praxi. 2025;26(3):212-216 | DOI: 10.36290/neu.2025.019

Current options for prophylactic treatment of migrain

MUDr. Jolana Mračková, Ph.D.
Neurologická klinika FN Plzeň

Migraine is a very common disease in the general population. It is associated with considerable disability and thus with a high socio-economic burden. Fortunately, recent years have brought fundamental new possibilities in both acute treatment of migraine attacks and prophylactic treatment, which aims to reduce the frequency and intensity of migraine attacks as much as possible. Another benefit of prophylactic treatment should optimally be the improvement of the response to acute treatment. Last but not least, prophylactic treatment should prevent the transformation of migraine from episodic to chronic form, and also eliminate the risk of developing headaches due to overuse of medication. Prophylactic migraine treatment includes many different drugs with different mechanisms of action, such as antihypertensive drugs, antidepressive medication, anticonvulsive medication, and in recent years, monoclonal antibodies against calcitonin gene-related peptide (CGRP) and gepants.

Keywords: migraine, treatment, prophylaxis, conventional drugs, monoclonal antibodies, gepants.

Received: February 22, 2025; Revised: February 22, 2025; Accepted: March 7, 2025; Prepublished online: March 7, 2025; Published: July 4, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mračková J. Current options for prophylactic treatment of migrain. Neurol. praxi. 2025;26(3):212-216. doi: 10.36290/neu.2025.019.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 4.7.2026

    References

    1. . Barbanti P, Aurilia C, Egeo G, et al.; Italian Migraine Registry study group. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Neurology. 2023 Sep 12;101(11):482-488. Go to original source... Go to PubMed...
    2. . Barbosa CD, Balp MM, Kulich K, et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39-48. Go to original source... Go to PubMed...
    3. . Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011 Feb;31(3):301-15. Go to original source... Go to PubMed...
    4. . Boyer N, Signoret-Genest J, Artola A, et al. Propranolol treatment prevents chronic central sensitization induced by repeated dural stimulation. Pain. 2017 Oct;158(10):2025-2034. Go to original source... Go to PubMed...
    5. . Danesh A, Gottschalk PCH. Beta-Blockers for Migraine Prevention: a Review Article. Curr Treat Options Neurol. 2019 Mar 23;21(4):20. doi: 10.1007/s11940-019-0556-3. Go to original source... Go to PubMed...
    6. . Ha H, Gonzalez A. Migraine Headache Prophylaxis. Am Fam Physician. 2019 Jan 1;99(1):17-24.
    7. . Jenkins B. Migraine management. Aust Prescr. 2020 Oct;43(5):148-151. Go to original source... Go to PubMed...
    8. . Lampl C, MaassenVanDenBrink A, Deligianni CI et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023 May 19;24(1):56. Go to original source... Go to PubMed...
    9. . Lipton RB, Bigal ME, Diamond M et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9. Go to original source... Go to PubMed...
    10. . Niedermayerová I. Profylaktická léčba migrény. Neurol. praxi. 2009; 10(6): 369-371.
    11. . Sprenger T, Viana M, Tassorelli C. Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. Neurotherapeutics. 2018 Apr;15(2):313-323. Go to original source... Go to PubMed...
    12. . Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137. Go to original source... Go to PubMed...
    13. . Tzankova V, Becker WJ, Chan TLH. Pharmacologic prevention of migraine. CMAJ. 2023 Feb 6;195(5):E187-E192. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.